Novo Holdings A/S’s Spero Therapeutics SPRO Stock Holding History

Novo Holdings A/S’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-468,902	Closed	-$628K	–	39
2024 Q3	$628K	Hold	468,902	–	–	0.03%	37
2024 Q2	$610K	Hold	468,902	–	–	0.03%	38
2024 Q1	$807K	Hold	468,902	–	–	0.06%	35
2023 Q4	$123M	Hold	468,902	–	–	7.62%	4
2023 Q3	$567K	Hold	468,902	–	–	0.04%	40
2023 Q2	$680K	Hold	468,902	–	–	0.05%	41
2023 Q1	$680K	Hold	468,902	–	–	0.04%	47
2022 Q4	$811K	Hold	468,902	–	–	0.05%	48
2022 Q3	$938K	Hold	468,902	–	–	0.04%	52
2022 Q2	$347K	Hold	468,902	–	–	0.02%	54
2022 Q1	$4.08M	Hold	468,902	–	–	0.22%	48
2021 Q4	$7.51M	Hold	468,902	–	–	0.36%	38
2021 Q3	$8.63M	Hold	468,902	–	–	0.45%	31
2021 Q2	$6.55M	Hold	468,902	–	–	0.29%	46
2021 Q1	$6.9M	Sell	468,902 -107,800	-19%	-$1.9M	0.29%	44
2020 Q4	$11.2M	Sell	576,702 -354,397	-38%	-$5.52M	0.48%	33
2020 Q3	$10.4M	Hold	931,099	–	–	0.52%	28
2020 Q2	$12.6M	Hold	931,099	–	–	0.81%	20
2020 Q1	$7.52M	Hold	931,099	–	–	0.5%	16
2019 Q4	$8.95M	Buy	931,099 +465,116	+100%	+$5.02M	0.58%	21
2019 Q3	$4.94M	Hold	465,983	–	–	0.85%	21
2019 Q2	$5.36M	Buy	+465,983	New	+$5.61M	0.75%	22

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Novo Holdings A/S's SPRO Position: Q4 2024 in Review

Novo Holdings A/S sold out of Spero Therapeutics (SPRO) in Q4 2024, closing a stake of 468,902 shares — an estimated $628K sold.

Novo Holdings A/S first reported a position in SPRO in Q2 2019 and held it in 22 quarters. The position peaked at $123M in Q4 2023. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2024.

Novo Holdings A/S reported no remaining Spero Therapeutics position as of Q4 2024 after selling out during the quarter.
Novo Holdings A/S sold 468,902 Spero Therapeutics shares in Q4 2024, an estimated $628K.
Novo Holdings A/S first reported a position in Spero Therapeutics in Q2 2019 and held it in 22 quarters.
Novo Holdings A/S's Spero Therapeutics position peaked at $123M in Q4 2023.
50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2024.

Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.